1. Solomón MT eres., Selva JC ésa., Figueredo J, Vaquer J, Toledo C, Quintanal N,
et al. Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma
patients: results from a randomized, double blind trial. BMC Cancer. 2013;13:299.
doi:10.1186/1471-2407-13-299.
3. Yang P, Wang Y, Peng X, You G, Zhang W, Yan W, et al. Management and survival rates
in patients with glioma in China (2004-2010): A retrospective study from a single-institution.
J Neurooncol. 2013;113:259–66.
4. Artene SA, Turcu-Stiolica A, Ciurea ME, Folcuti C, Tataranu LG, Alexandru O, et
al. Comparative effect of immunotherapy and standard therapy in patients with high
grade glioma: a meta-analysis of published clinical trials. Sci Rep. 2018;8:1–10.
5. Cao JX, Zhang XY, Liu JL, Li D, Li JL, Liu YS, et al. Clinical efficacy of tumor
antigen-pulsed dc treatment for high-grade glioma patients: Evidence from a meta-analysis.
PLoS One. 2014;9.
6. Wang X, Zhao HY, Zhang FC, Sun Y, Xiong ZY, Jiang XB. Dendritic cell-based vaccine
for the treatment of malignant glioma: A systematic review. Cancer Invest. 2014;32:451–7.
7. Zhao F, Tian J, An L, Yang K. Prognostic utility of gene therapy with herpes simplex
virus thymidine kinase for patients with high-grade malignant gliomas: A systematic
review and meta analysis. J Neurooncol. 2014;118:239–46.
8. Hanaei S, Afshari K, Hirbod-Mobarakeh A, Mohajer B, Amir Dastmalchi D, Rezaei N.
Therapeutic efficacy of specific immunotherapy for glioma: a systematic review and
meta-analysis. Rev Neurosci. 2018;29:443–61.
9. Liu T. Efficacy and safety analysis on dendritic cell-based vaccine-treated high-grade
glioma patients : a systematic review and meta-analysis. Onco Targets Ther. 2018;:7277–93.
10. Jayne F Tierney*1, Lesley A Stewart2, Davina Ghersi3 SB and MRS. Response to:
Practical methods for incorporating summary time-to-event data into meta-analysis.
Trials. 2013;14:1–16.
11. Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions:
Cochrane Book Series. 2008.
12. Wells G, Shea B, O’Connell J. The Newcastle-Ottawa Scale (NOS) for Assessing The
Quality of Nonrandomised Studies in Meta-analyses. Ottawa Heal Res Inst Web site.
2014;7.
13. Wells GA et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality if
nonrandomized studies in meta-analyses. Evid based public Heal. 2012.
14. Lim M, Xia Y, Bettegowda C, Weller M. Current state of immunotherapy for glioblastoma.
Nature Reviews Clinical Oncology. 2018;15:422–42.
15. Carpentier AF, Lambert J. Intracerebral injection of CpG oligonucleotide for patients
with de novo glioblastoma—A phase II multicentric, randomised study. Eur J Cancer.
2017;73:30–7.
16. Yao Y, Luo F, Tang C, Chen D, Qin Z, Hua W, et al. Molecular subgroups and B7-H4
expression levels predict responses to dendritic cell vaccines in glioblastoma: an
exploratory randomized phase II clinical trial. Cancer Immunol Immunother. 2018;67:1777–88.
doi:10.1007/s00262-018-2232-y.
17. Schneider JR, Patel N V., Kwan K, Boockvar JA. Recurrent Glioblastoma Treated
With Recombinant Poliovirus. Neurosurgery. 2018;83:E200.
18. Omuro A, Vlahovic G, Lim M, Sahebjam S, Baehring J, Cloughesy T, et al. Nivolumab
with or without ipilimumab in patients with recurrent glioblastoma: Results from exploratory
phase i cohorts of CheckMate 143. Neuro Oncol. 2018;20:674–86.
19. Blumenthal GM, Zhang L, Zhang H, Kazandjian D, Khozin S, Tang S, et al. Milestone
analyses of immune checkpoint inhibitors, targeted therapy, and conventional therapy
in metastatic non–small cell lung cancer trials: A meta-analysis. JAMA Oncol. 2017;3.
20. Ji N, Weng D, Liu C, Gu Z, Chen S, Guo Y, et al. Adenovirus-mediated delivery
of herpes simplex virus thymidine kinase administration improves outcome of recurrent
high-grade glioma. Oncotarget. 2016;7. doi:10.18632/oncotarget.6737.
21. Immonen A, Vapalahti M, Tyynelä K, Hurskainen H, Sandmair A, Vanninen R, et al.
AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant
glioma: A randomised, controlled study. Mol Ther. 2004;10:967–72.
22. Vik-Mo EO, Nyakas M, Mikkelsen BV, Moe MC, Due-Tønnesen P, Suso EMI, et al. Therapeutic
vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells
in patients with glioblastoma. Cancer Immunol Immunother. 2013;62:1499–509.
23. Jie X, Hua L, Jiang W, Feng F, Feng G, Hua Z. Clinical Application of a Dendritic
Cell Vaccine Raised Against Heat-Shocked Glioblastoma. Cell Biochem Biophys. 2012;62:91–9.
24. Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H, et al. Rindopepimut with
temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT
IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol. 2017;18:1373–85.
25. Wheeler LA, Manzanera AG, Bell SD, Cavaliere R, McGregor JM, Grecula JC, et al.
Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to
surgical resection for newly diagnosed malignant glioma. Neuro Oncol. 2016;18:1137–45.
26. Rainov NG. A Phase III Clinical Evaluation of Herpes Simplex Virus Type 1 Thymidine
Kinase and Ganciclovir Gene Therapy as an Adjuvant to Surgical Resection and Radiation
in Adults with Previously Untreated Glioblastoma Multiforme. Hum Gene Ther. 2000;11:2389–401.
doi:10.1089/104303400750038499.
27. Wick W, Gorlia T, Bendszus M, Taphoorn M, Sahm F, Harting I, et al. Lomustine
and Bevacizumab in Progressive Glioblastoma. N Engl J Med. 2017;377:1954–63. doi:10.1056/NEJMoa1707358.